^
Association details:
| Biomarker: | HER-2 expression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | trastuzumab rezetecan (SHR-A1811) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
656MO - The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): Results from the global phase I study
Published date:
10/16/2023
Excerpt:
SHR-A1811 had favorable antitumor activity and acceptable safety profile in heavily pretreated HER2-expressing/mutated advanced non-breast STs, including BTC, UC, GC/GEJA, and CRC.
Trial ID:
Source:
Title:
684P - Phase I trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC)
Published date:
10/16/2023
Excerpt:
The respective 6-mo PFS rates in GC/GEJ and in HER2-positve GC/GEJ at RP2D were 71.0% (95% CI 54.0-82.7) and 73.9% (95% CI 52.1-86.9); the corresponding rates in CRC were 75.6% (95% CI 57.9-86.6) and 85.5% (95% CI 65.6-94.3)….SHR-A1811 showed an acceptable safety profile and promising clinical activity in pts with HER2-expressing GC/GEJ and CRC.
Trial ID:
